GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination.

Autor: Bekris LM; Department of Medicine, University of Washington, Seattle, WA 98195, USA., Jensen RA, Lagerquist E, Hall TR, Agardh CD, Cilio CM, Lethagen AL, Lernmark A, Robertson JA, Hampe CS
Jazyk: angličtina
Zdroj: Diabetic medicine : a journal of the British Diabetic Association [Diabet Med] 2007 May; Vol. 24 (5), pp. 521-6. Date of Electronic Publication: 2007 Mar 15.
DOI: 10.1111/j.1464-5491.2007.02091.x
Abstrakt: Aims: Subcutaneous injection of recombinant human GAD65 (rhGAD65) in patients with latent autoimmune diabetes in adults (LADA) correlates with an increase in C-peptide levels. In this study we analysed the effect of rhGAD65 administration on the GAD65-specific autoimmune response.
Methods: Longitudinal serum samples obtained from LADA patients (n = 47) who received 4, 20, 100 or 500 microg alum-formulated rhGAD65 or placebo by subcutaneous injection twice (4 weeks apart) were analysed for their epitope recognition using GAD65-specific recombinant Fab and GAD65/67 fusion proteins.
Results: Overall, minor changes in the epitope pattern were observed using either approach. Only in the 500-microg dosage group was an increase in GAD65Ab level associated with a significant increase in the binding to a conformational epitope located at the middle part of GAD65.
Conclusions: Our data suggest that the apparent beneficial effects of 20 microg alum-formulated recombinant human GAD65 is not explained by changes in the GAD65Ab epitope pattern.
Databáze: MEDLINE
Externí odkaz: